Intensive lipid lowering with a regimen of statins plus a PCSK9 inhibitor in the 12 months after an acute coronary syndrome (ACS) appears to have benefits in modulating plaque phenotype, which is likely to lead to early reductions in cardiovascular risk, according to results from HUYGENS, presented Friday at the virtual European Society of Cardiology Congress 2021 by investigator Stephen J. Nicholls, MBBS, PhD.